PTX100 - Driving the future, page-2

Case Study - Kura Oncology - listed on Nasdaq - $636 M USD market cap $916 M AUD. Pipeline includes Tipifarnib. Most advanced indication is for head & neck cancer. Results on Ph 2 - 18 Pts - ORR of 56% partial responses achieved - no CR - moving to Pivotal trial for HRAS mutated head & neck cancers; similarities to PTX; 3 molecules in the pipeline, personalised therapy (specific to mutation/ biomarker) no approved therapies, 1 Phase 2, 1 Phase 1, 1 Preclinical. PTX 81% ORR one indication, Car-T asset in preclinical, CR's achieved,...